AcuCort has received approval for the company's first drug Zeqmelit® in Finland from the Finnish drug monitoring agency, Fimea. Thus, Zeqmelit® has been approved in all Nordic countries. In the development of the drug Zeqmelit®, AcuCort has succeeded in combining the advantages of the well-proven substance dexamethasone and a patented user-friendly oral film for quick availability and relief in emergency situations such as severe and acute allergic reactions.

Zeqmelit® has previously been approved by pharmaceutical authorities in Sweden, Norway and Denmark. AcuCort's objective is to commercialize Zeqmelit® globally, i.e. in the EU, USA and in selected key markets.